Shares of Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) have received a consensus rating of “Moderate Buy” from the twelve research firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $233.58.
Several equities analysts recently weighed in on INSP shares. Wells Fargo & Company increased their price target on shares of Inspire Medical Systems from $187.00 to $198.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Piper Sandler restated an “overweight” rating and set a $260.00 price target (up previously from $255.00) on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Truist Financial reiterated a “buy” rating and issued a $240.00 price objective (up previously from $217.00) on shares of Inspire Medical Systems in a research note on Monday, September 30th. Bank of America raised Inspire Medical Systems from a “neutral” rating to a “buy” rating and raised their target price for the stock from $220.00 to $255.00 in a research report on Wednesday, November 20th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $200.00 price target (up previously from $170.00) on shares of Inspire Medical Systems in a research report on Tuesday, November 5th.
View Our Latest Report on INSP
Institutional Inflows and Outflows
Inspire Medical Systems Stock Performance
Shares of INSP stock opened at $175.75 on Tuesday. Inspire Medical Systems has a 52-week low of $123.00 and a 52-week high of $257.40. The company has a 50-day simple moving average of $191.37 and a two-hundred day simple moving average of $184.30. The company has a market capitalization of $5.27 billion, a price-to-earnings ratio of 164.25 and a beta of 1.32.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.54. The company had revenue of $203.20 million during the quarter, compared to the consensus estimate of $197.59 million. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. Inspire Medical Systems’s revenue was up 32.6% on a year-over-year basis. During the same period last year, the business posted ($0.29) earnings per share. On average, sell-side analysts forecast that Inspire Medical Systems will post 1.33 EPS for the current fiscal year.
About Inspire Medical Systems
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
Featured Stories
- Five stocks we like better than Inspire Medical Systems
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- What is a SEC Filing?
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- What is a buyback in stocks? A comprehensive guide for investors
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.